How Does Mometasone Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Mometasone Works
- Active Ingredient: Mometasone furoate (as monohydrate) – a synthetic corticosteroid with high affinity for glucocorticoid receptors.
- Primary Action: Reduces inflammation by suppressing pro‑inflammatory mediators (cytokines, chemokines) in nasal mucosa.
- Onset & Duration: Symptom relief begins within 12 hours; full effect after 1‑2 weeks of regular once‑daily use.
- Metabolism: Extensively metabolised in liver via CYP3A4 to inactive metabolites; excreted mainly in faeces.
- Indications: Allergic rhinitis (seasonal/perennial) in adults and children ≥3 years; nasal polyps in adults ≥18 years.
Mometasone furoate nasal spray is a locally‑acting corticosteroid that controls the inflammation underlying allergic rhinitis and nasal polyps. This page explains its precise pharmacological action, from molecular structure to clinical outcomes.
Important Medical Advice
Stop using mometasone and seek immediate medical help if you experience swelling of the face, tongue, or throat, difficulty swallowing, hives, wheezing, or trouble breathing – these may be signs of a severe allergic reaction. Do not use during an untreated nasal infection (e.g., herpes) or immediately after nasal surgery until healing is complete.
Chemical Composition & Molecular Structure
Mometasone furoate is a synthetic corticosteroid with the chemical name 9,21‑dichloro‑11β,17‑dihydroxy‑16α‑methylpregna‑1,4‑diene‑3,20‑dione 17‑(2‑furoate). Its molecular formula (free base) is C27H30Cl2O6 and molecular weight 521.4 g/mol. The drug is formulated as the monohydrate in a white, aqueous suspension for intranasal use.
Structural & Formulation Details
High‑lipophilicity corticosteroid
The furoate ester at the 17‑position enhances lipophilicity (logP 3.8), promoting rapid uptake into cells and prolonged retention in nasal tissue. The dichloro substitution increases glucocorticoid receptor selectivity.
Glycerol, microcrystalline cellulose, carmellose sodium, citric acid monohydrate, polysorbate 80, benzalkonium chloride, sodium citrate dihydrate, water for injection
Benzalkonium chloride acts as a preservative; polysorbate 80 helps stabilise the suspension. The cellulose derivatives maintain even dispersion.
Key Pharmaceutical Properties
| Property | Value |
|---|---|
| Lipophilicity (logP) | 3.8 |
| Protein binding | 98‑99% |
| Oral bioavailability | <1% (extensive first‑pass) |
| Receptor affinity (relative to dexamethasone) | ~1200 |
🗒️ Pharmaceutical insight: The high lipophilicity and receptor affinity allow mometasone to be effective at microgram doses with minimal systemic absorption.
Mechanism of Action: Mometasone Pathway
Mometasone exerts its therapeutic effect through genomic and non‑genomic pathways, ultimately dampening the allergic inflammatory cascade.
- Glucocorticoid receptor binding: After diffusion into target cells (epithelial, eosinophils, mast cells), mometasone binds to cytoplasmic glucocorticoid receptors with high affinity. The drug‑receptor complex translocates to the nucleus.
- Transrepression: In the nucleus, the complex interferes with transcription factors (NF‑κB, AP‑1), suppressing the expression of pro‑inflammatory cytokines (IL‑4, IL‑5, IL‑13), chemokines, and adhesion molecules.
- Transactivation: It also increases transcription of anti‑inflammatory proteins (lipocortin‑1, IL‑10), further resolving inflammation.
- Clinical correlates: Reduced eosinophil infiltration, decreased mucus secretion, and diminished nasal mucosa oedema lead to relief of sneezing, itching, rhinorrhoea, and congestion.
| Component | Effect |
|---|---|
| Eosinophils | Apoptosis, reduced chemotaxis |
| Mast cells | Stabilisation, decreased histamine release |
| Epithelial cells | Reduced cytokine production |
| Endothelial cells | Decreased vascular permeability |
🗒️ Physiological insight: The rapid onset (within 12 hours) may involve non‑genomic effects, while full therapeutic benefit requires regular use over days due to genomic regulation.
Absorption & Distribution (Pharmacokinetics)
Following intranasal administration, a fraction of the dose is retained in the nasal cavity; the remainder is swallowed. Systemic absorption from the nasal mucosa is minimal (<0.1% of nominal dose) due to low solubility and extensive first‑pass metabolism of the swallowed portion.
Local deposition
Approximately 70‑80% of each spray deposits on the nasal mucosa; the drug dissolves slowly, prolonging local availability.
Systemic exposure
Plasma concentrations after therapeutic doses are usually below the limit of quantification (pg/mL range). Protein binding is 98‑99%, rendering the free fraction negligible.
Volume of distribution
Not clinically relevant for nasal use; however IV studies show a large Vd (~ 350 L) indicating extensive tissue distribution.
Metabolic Effects & Elimination
Metabolism: The small amount of mometasone that reaches the systemic circulation is rapidly metabolised in the liver, primarily by the CYP3A4 isoenzyme, to multiple hydroxylated metabolites. These metabolites are pharmacologically inactive.
Elimination: Over 90% of an absorbed dose is excreted via the bile into faeces; less than 1% appears in urine as unchanged drug or metabolites. The terminal half‑life after intravenous administration is approximately 5.8 hours, but this is not relevant for nasal therapy due to negligible systemic levels.
⚠️ Metabolic caution: Potent CYP3A4 inhibitors (e.g., ritonavir, cobicistat) may increase systemic mometasone levels, although clinical significance is low with nasal use. Monitor if co‑prescribed.
Clinical Efficacy in Rhinitis and Nasal Polyps
Allergic rhinitis (seasonal/perennial): Mometasone furoate nasal spray reduces nasal symptoms (sneezing, itching, rhinorrhoea, congestion) and ocular symptoms in many patients. Improvement begins within 12 hours after the first dose, but maximal benefit is achieved after 1‑2 weeks of regular use. It is licensed for adults and children ≥3 years (usual dose: one or two sprays per nostril once daily).
Nasal polyps: In adults (≥18 years), mometasone shrips existing polyps and prevents regrowth. The recommended starting dose is two sprays in each nostril once daily; if no response after 5‑6 weeks, it may be increased to twice daily. Regular use reduces nasal obstruction and improves quality of life.
- Onset for polyps: Symptom improvement may take several weeks; if no benefit after 5‑6 weeks of twice‑daily dosing, reassess treatment.
- Steroid‑sparing effect: Mometasone can reduce the need for oral corticosteroids in polyp patients.
🗒️ Trial data: In clinical studies, mometasone significantly improved peak nasal inspiratory flow and reduced polyp size compared to placebo, with a favourable safety profile.
Mometasone FAQs
How quickly does mometasone nasal spray start working?
Some symptom relief (e.g., nasal congestion) may occur within 12 hours after the first dose. However, maximum benefit usually requires 1‑2 weeks of regular once‑daily use.
Can mometasone be used in children?
Yes, for allergic rhinitis it is licensed for children aged 3 years and older. The dose is one spray in each nostril once daily. For nasal polyps, it is only for adults 18+.
What are the most common side effects?
Common side effects include headache, sneezing, nosebleeds, nasal ulceration, and sore throat. These are usually mild and transient.
Can I use mometasone if I have an infection?
Do not use if you have an untreated nasal infection (e.g., cold sores, herpes). Wait until the infection has cleared. If you develop a new infection while using it, consult your doctor.
Is mometasone safe during pregnancy?
There is limited data; use only if clearly needed and prescribed by your doctor. Uncontrolled allergic rhinitis itself may pose risks, so discuss benefits and risks with your healthcare provider.
Need Mometasone with Expert Guidance?
If you suffer from hay fever, perennial rhinitis, or nasal polyps, a UK‑registered doctor can assess your symptoms and provide a prescription online.
Secure Prescription & Next-Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Allergy ConsultationRelated Mometasone Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Feroz is a GMC-registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 12 March 2026
Next Review: 12 September 2026
Published on: 12 March 2026
Last Updated: 12 March 2026